Aardvark prices $94.2m IPO to fund development of Prader-Willi syndrome drug
Aardvark’s lead candidate ARD-101 is being investigated in a Phase III study for hyperphagia in Prader-Willi syndrome.
IPO Industry
Ascentage Pharma raises $126m in first biotech IPO of 2025
Bicara Therapeutics closes $362m IPO in flurry of biotech listing activity
Global stock market crash likely to delay biotech IPOs
Money moves: How the biotech market is weathering inflationary storms
Valneva receives up to £20m vaccine R&D funding in Scotland
Covid-19 update: Yellen calls for new fund to tackle future health crises
Ventus Therapeutics raises funding to expedite drug discovery platform
